A single institution experience of streptozocin/fluorouracil combination chemotherapy: a case series
- 146 Downloads
The combination chemotherapy regimen of streptozocin and 5-fluorouracil (FU/STZ) has been used for the treatment of metastatic neuroendocrine tumours.
The aim of this study was to analyse the use of this regimen in a tertiary oncology referral centre over a 10-year period.
We retrospectively analysed nine cases from February 2000 to May 2010. Patient demographics, chemotherapy schedule, toxicities, progression-free and overall survival were tabulated for each patient.
The median progression-free survival was 17 months (range 3–48+ months), and overall survival 31 months (range 12–53+ months) with no toxicity related deaths.
FU/STZ was a well-tolerated regimen that produced significant benefit in the setting of metastatic and progressive disease. Our case series demonstrated comparable progression-free survival and overall survival in relation to randomized controlled studies and previous case series.
KeywordsStreptozocin Fluorouracil Metastatic Neuroendocrine Tumour
Conflict of interest
- 12.Phan A, Yao J, Fogelman D. (2010) A prospective, multi-institutional phase II study of GW786034 (pazopanib) and depot octreotide in advanced low-grade neuroendocrine carcinoma J Clin Oncol 28 (absract)Google Scholar
- 13.Hobday TJ, Rubin J, Holen K, Picus J, Donehower R, Marschke R, Maples W, Lloyd R, Mahoney M, Erlichman C (2007) MC044 h, a phase II trial of sorafenib in patients with metastatic neuroendocine tumors: a phase II consortium study [abstract]. ASCO Annual Meeting Proc 25:4505aGoogle Scholar
- 16.Castellano D (2011) Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumor: a phase II study of the Spanish Neuroendocrine Tumor Group (GETNE0801)Google Scholar